The COVID Advisor

Background Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID. Methods We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30–85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assign...

Introduction and Context The concept of "turbo cancer"—rapidly progressing cancers allegedly linked to COVID-19 mRNA vaccines—has gained widespread attention. A recent preprint study (July 2025) exploring transcriptomic dysregulation in individuals with new-onset adverse events or cancers following mRNA vaccination introduces preliminary molecular data that may warrant further investigation. This article critically reviews the origins of the "turbo cancer" narrative, current scientific literature including emerging molecular studies, and emphasizes the need for evidence-based analysis when considering health claims related to vaccination.  This independent article aims to cut through the noise by providing a fact-based exploration of 'turbo cancer' or 'aggressive cancer'. Drawing on peer-reviewed studies, expert insights, and data from health authorities, we unpack common claims, clarify the science, and address lingering myths.  Our goal is to empo...

A sudden rise in younger people with early onset cancers which are more aggressive with more (and unusual) genetic change has been increasingly noted - colorectal, breast and GI tract cancers seem to lead the way. October 2025 Study: Genomic Integration and Molecular Dysregulation in Aggressive Stage IV Bladder Cancer Following COVID-19 mRNA Vaccination Bladder cancer is rare in young women, and advanced presentations are exceptionally uncommon. Authors report a de-identified case of a previously healthy 31-year-old female who developed rapidly progressive stage IV bladder cancer within 12 months of completing a three-dose Moderna mRNA vaccination series (May 2021, June 2021, December 2021). ( International Journal of Innovative Research in Medical Science ) This sentinel case report provides the first documented evidence of genomic integration of mRNA vaccine-derived genetic material in a human subject, documenting a temporal association between COVID-19 mRNA vaccination and aggre...